Previously known as California Biotechnology Inc, the firm was first renamed Scios Nova Inc and then Scios. The firm was an early established biopharmaceutical company engaged in the discovery, development, manufacture and commercialization of novel human therapeutics. Acquired in a very large all-cash transaction in 2003 by J&J., there was a conscious effort by all parties to maintain the small business feeling and in-house energy, Scios Inc. has continued to be a biopharmaceutical company developing novel treatments for cardiovascular disease, inflammatory disease and cancer. With working relationships in our varaitions with many of the leading large players in the space, as well as their contemporaries, Scios' disease-based technology platform integrated expertise in protein biology with computational and medicinal chemistry. The effort was to identify novel targets and rationally design small molecule compounds and peptides for markets with unmet medical needs.
